Advertisement

Tumor Biology

, Volume 36, Issue 11, pp 8295–8299 | Cite as

Postoperative dynamic changes in the concentration of CK19-2G2 in lung cancer patients and the clinical value of this marker

  • Jia Gao
  • Fang Lv
  • Jiwen Wang
  • Zongyong Wu
  • Jia Li
  • Cuie Yan
  • Jun Qi
Research Article
  • 94 Downloads

Abstract

CK19-2G2, a newly identified fragment of cytokeratin 19, is a candidate marker for the diagnosis of lung cancer and for monitoring a patient’s response to lung cancer treatment. This study investigated the postoperative dynamic changes in serum CK19-2G2 concentration and the clinical value of this marker in lung cancer patients. Preoperative and postoperative concentrations of CK19-2G2 were measured in 352 lung cancer patients who had undergone pulmonary resection. Stratified analyses based on pathologic types and lymph node involvement were performed to determine their possible impacts on postoperative CK19-2G2 concentration. CK19-2G2 concentration was significantly lower after tumor resection than before tumor resection. For squamous cell carcinoma patients, the postoperative CK19-2G2 concentration had decreased significantly at 1 week after surgery and had decreased further at 1 month after surgery. For adenocarcinoma patients, there were little changes in the CK19-2G2 concentration during 1 week to 1 month after surgery. At 1 week after surgery, the CK19-2G2 concentration was slightly higher in patients with N2 stage disease than in those with N0 and N1 stage disease, and this difference increased at 1 month after surgery. Postoperative CK19-2G2 concentration may be an indicator of prognosis. An increase after the initial drop in CK19-2G2 concentration after surgery may indicate a poor prognosis.

Keywords

Lung cancer Cytokeratin 19 CK19-2G2 

Notes

Conflicts of interest

None.

References

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Fiala O, Pesek M, Finek J, Benesova L, Minarik M, Bortlicek Z, et al. Predictive role of CEA and CYFRA 21–1 in patients with advanced-stage NSCLC treated with erlotinib. Anticancer Res. 2014;34(6):3205–10.PubMedGoogle Scholar
  3. 3.
    Ono A, Takahashi T, Mori K, Akamatsu H, Shukuya T, Taira T, et al. Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study. BMC Cancer. 2013;13:354.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Liang ZK, Yin YJ, Wu ED, Shi GL. The clinical value of new tumor biomarker cytokeratin 2G2 detection in non-small cell lung cancer patients. Clin Lab. 2013;59(5–6):551–6.PubMedGoogle Scholar
  5. 5.
    Gao J, Lv F, Li J, Wu Z, Qi J. Serum cytokeratin 19 fragment, CK19-2G2, as a newly identified biomarker for lung cancer. PLoS One. 2014;9(7), e101979.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kong Y, Wang J, Liu W, Chen Q, Yang J, Wei W, et al. Cytokeratin19-2g2, a novel fragment of cytokeratin19 in serum, indicating a more invasive behavior and worse prognosis in breast cancer patients. PLoS One. 2013;8(2), e57092.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Cui C, Sun X, Zhang J, Han D, Gu J. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis. J Cancer Res Ther. 2014;10(Suppl):C131–4.PubMedGoogle Scholar
  8. 8.
    Yang L, Chen X, Li Y, Yang J, Tang L. Declines in serum CYFRA21-1 and carcinoembryonic antigen as predictors of chemotherapy response and survival in patients with advanced non-small cell lung cancer. Exp Ther Med. 2012;4(2):243–8.PubMedGoogle Scholar
  9. 9.
    Cedres S, Nunez I, Longo M, Martinez P, Checa E, Torrejon D, et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2011;12(3):172–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Suzuki M, Matsuzuka T, Hashimoto Y, Ikeda M, Saijo S, Omori K. Diagnostic potential of one-step nucleic acid amplification assay in patients with head and neck squamous cell carcinoma based on CK19 expression in a primary lesion. Head Neck. 2014. doi: 10.1002/hed.23979.Google Scholar
  11. 11.
    Nagler RM, Barak M, Peled M, Ben-Aryeh H, Filatov M, Laufer D. Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21–1 and TPS in oral squamous cell carcinoma. Cancer. 1999;85(5):1018–25.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Jia Gao
    • 1
  • Fang Lv
    • 2
  • Jiwen Wang
    • 3
  • Zongyong Wu
    • 1
  • Jia Li
    • 1
  • Cuie Yan
    • 1
  • Jun Qi
    • 1
  1. 1.Clinical Laboratory, Cancer Institute and HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina
  2. 2.Department of Thoracic Surgery, Cancer Institute and HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina
  3. 3.Departments of Thoracic SurgeryZhejiang Cancer HospitalHangzhouChina

Personalised recommendations